Journal List > Korean J Gastroenterol > v.64(3) > 1007270

Park, Huh, Shin, Lee, Yoon, Song, Min, Choi, and The Korean Society of Neurogastroenterology and Motility: Current Issues in Functional Dyspepsia

Abstract

Functional dyspepsia is one of the most common gastrointestinal disorders encountered in clinical practice. Functional dyspepsia is currently defined by Rome III criteria as the chronic dyspeptic symptoms (postprandial fullness, early satiety, epigastric pain or burning) in the absence of underling structural or metabolic disease that readily explain the symptoms. According to the Rome III consensus, functional dyspepsia can be subdivided into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Although the Rome III criteria have been published more than 8 years ago, not much effort has been put into validating these criteria and direct scientific evidence supporting the validity of the subdividing functional dyspepsia into PDS and EPS are lacking. This article is intended to review the validity of the Rome III criteria on the subdivisions of functional dyspepsia, i.e. PDS and EPS. The impact of sleep disorder, Helicobacter pylori-associated dyspepsia, and the emerging drug therapies in functional dyspepsia will also be discussed in this article.

References

1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemo-graphy, and health impact. Dig Dis Sci. 1993; 38:1569–1580.
2. El-Serag HB, Talley NJ. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther. 2003; 18:387–393.
crossref
3. Nyrén O, Lindberg G, Lindström E, Marké LA, Seensalu R. Economic costs of functional dyspepsia. Pharmacoeconomics. 1992; 1:312–324.
crossref
4. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009; 137:94–100.
crossref
5. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130:1466–1479.
crossref
6. Lee YY, Wahab N, Mustaffa N, et al. A Rome III survey of functional dyspepsia among the ethnic Malays in a primary care setting. BMC Gastroenterol. 2013; 13:84.
crossref
7. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology. 2014; 146:932–940.e1.
crossref
8. Goldsmith G, Levin JS. Effect of sleep quality on symptoms of irritable bowel syndrome. Dig Dis Sci. 1993; 38:1809–1814.
crossref
9. Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008; 43:833–841.
crossref
10. Futagami S, Yamawaki H, Izumi N, et al. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol. 2013; 28:1314–1320.
crossref
11. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005; 129:1756–1780.
crossref
12. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012; 27:626–641.
crossref
13. Suzuki H, Matsuzaki J, Hibi T. What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? J Neurogastroenterol Motil. 2011; 17:124–130.
14. Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol. 2008; 43:251–255.
crossref
15. Abid S, Siddiqui S, Jafri W. Discriminant value of Rome III questionnaire in dyspeptic patients. Saudi J Gastroenterol. 2011; 17:129–133.
crossref
16. Vakil N, Talley N, van Zanten SV, et al. STARS I Study Group. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol. 2009; 7:756–761.
crossref
17. Kim ES, Lee BJ, Kim YS, Lee SI, Park H. Validation of Rome III criteria in the diagnosis of functional gastrointestinal disorders in Korean patients. Korean J Neurogastroenterol Motil. 2008; 14:39–44.
18. Song KH, Jung HK, Min BH, et al. Development and validation of the Korean Rome III questionnaire for diagnosis of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2013; 19:509–515.
crossref
19. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006; 23:923–936.
crossref
20. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology. 2006; 130:296–303.
crossref
21. Laheij RJ, De Koning RW, Horrevorts AM, et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol. 2004; 38:490–495.
crossref
22. Piessevaux H, De Winter B, Louis E, et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil. 2009; 21:378–388.
crossref
23. Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol. 2004; 2:985–996.
crossref
24. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology. 2010; 138:1302–1311.
crossref
25. Min BH, Huh KC, Jung HK, et al. Functional Dyspepsia Study Group of Korean Society of Neurogastroenterology and Motility. Prevalence of uninvestigated dyspepsia and gastroesophageal reflux disease in Korea: a population-based study using the Rome III criteria. Dig Dis Sci. 2014. [Epub ahead of print].
crossref
26. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 1999; 45(Suppl 2):II37–II42.
crossref
27. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008; 8:43.
crossref
28. Park JM, Choi MG, Cho YK, et al. Functional gastrointestinal disorders diagnosed by Rome III questionnaire in Korea. J Neurogastroenterol Motil. 2011; 17:279–286.
crossref
29. Haag S, Senf W, Tagay S, et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol Motil. 2010; 22:262–e79.
crossref
30. Shindo T, Futagami S, Hiratsuka T, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and nonerosive reflux disease. Digestion. 2009; 79:65–72.
crossref
31. Ahmed AB, Matre K, Hausken T, Gregersen H, Gilja OH. Rome III subgroups of functional dyspepsia exhibit different characteristics of antral contractions measured by strain rate imaging: a pilot study. Ultraschall Med. 2012; 33:E233–E240.
32. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-con-trol study. Clin Gastroenterol Hepatol. 2007; 5:1175–1183.
crossref
33. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocy-tosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009; 29:765–773.
crossref
34. Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105:1835–1842.
crossref
35. Walker MM, Aggarwal KR, Shim LS, et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014; 29:474–479.
crossref
36. Oshima T, Nakajima S, Yokoyama T, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet. 2010; 11:13.
crossref
37. Shimpuku M, Futagami S, Kawagoe T, et al. G-protein β3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hun-ger in Japanese. Neurogastroenterol Motil. 2011; 23:1073–1080.
crossref
38. Park HY, Jahng JH, Lee YJ, Park HJ, Lee SI. Serotonin transporter gene and G-protein β3 C825T gene polymorphism in patients with functional dyspepsia and irritable bowel syndrome. Korean J Neurogastroenterol Motil. 2009; 15:58–64.
39. Kim HG, Lee KJ, Lim SG, Jung JY, Cho SW. G-protein beta3 subunit C825T polymorphism in patients with overlap syndrome of functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil. 2012; 18:205–210.
crossref
40. Park CS, Uhm JH. Polymorphisms of the serotonin transporter gene and G-protein β3 subunit gene in Korean children with irritable bowel syndrome and functional dyspepsia. Gut Liver. 2012; 6:223–228.
crossref
41. Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10:187–194.
crossref
42. Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012; 18:150–168.
crossref
43. Hsu YC, Liou JM, Yang TH, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol. 2011; 46:183–190.
crossref
44. Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol. 2010; 105:2626–2631.
crossref
45. Futagami S, Shimpuku M, Song JM, et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion. 2012; 86:114–121.
crossref
46. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 2011; 171:1929–1936.
47. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009; 21:272–280.
crossref
48. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012; 61:821–828.
crossref
49. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003; 65:528–533.
50. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey con-ducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98:1487–1493.
crossref
51. Yi CH, Hu CT, Chen CL. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. Am J Med Sci. 2007; 334:168–170.
crossref
52. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol. 2011; 9:410–414.
crossref
53. Yamawaki H, Futagami S, Shimpuku M, et al. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil. 2014; 20:104–112.
crossref
54. Lu CL, Chang SS, Wang SS, Chang FY, Lee SD. Silent peptic ulcer disease: frequency, factors leading to “silence,” and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc. 2004; 60:34–38.
crossref
55. Wang FW, Tu MS, Mar GY, et al. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World J Gastroenterol. 2011; 17:1199–1203.
crossref
56. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol. 2004; 39:97–103.
57. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 2008; 47:1077–1083.
58. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, Ten Kate FJ. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol. 2005; 58:927–931.
59. Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol. 2013; 108:1558–1563. quiz 1564.
crossref
60. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010; 16:30–34.
crossref
61. D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter. 2009; 14(Suppl 1):21–28.
62. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology. 2007; 132:2116–2130.
crossref
63. Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW. Plasma ghrelin levels and their relationship with gastric emptying in patients with dys-motility-like functional dyspepsia. Digestion. 2009; 80:58–63.
crossref
64. Kawashima J, Ohno S, Sakurada T, et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol. 2009; 44:1046–1054.
crossref
65. Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005; 90:10–16.
66. Takamori K, Mizuta Y, Takeshima F, et al. Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol. 2007; 41:477–483.
crossref
67. Akamizu T, Iwakura H, Ariyasu H, et al. FD Clinical Study Team. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur J Endocrinol. 2008; 158:491–498.
crossref
68. Saito Y, Suzuki H, Tsugawa H, et al. Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology. 2011; 140:189–198.
69. Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011; 26(Suppl 3):42–45.
70. Sugano K. Should we still subcategorize Helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011; 17:366–371.
71. Lee H, Jung HK, Huh KC. Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med. 2014; 29:156–165.
crossref
72. Jee SR, Jung HK, Min BH, et al. Korean Society of Neurogastroenterology and Motility. Guidelines for the treatment of functional dyspepsia. Korean J Gastroenterol. 2011; 57:67–81.
crossref
73. Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002; 16:959–967.
crossref
74. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A place-bo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354:832–840.
crossref
75. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, dou-ble-blind, placebo-controlled trials. Gut. 2008; 57:740–746.
crossref
76. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008; 103:1906–1919.
crossref
77. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut. 2005; 54:455–460.
crossref
78. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008; 8:690–696.
crossref
79. McCallum RW, Lembo A, Esfandyari T, et al. TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013; 25:e705–e717.
crossref
80. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998; 115:1346–1352.
crossref
81. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012; 10:1239–1245.
crossref
82. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009; 104:2779–2787.
crossref
83. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012; 24:540–e251.
crossref
84. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia: 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010; 22:618–e173.
85. Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol. 2005; 40:1036–1042.
crossref
86. van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the anti-depressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008; 6:746–752. quiz 718.
87. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of ami-triptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011; 34:638–648.
crossref
88. Read NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut. 1997; 41:664–668.
crossref
89. Talley NJ, Choung RS, Camilleri M, Dierkhising RA, Zinsmeister AR. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther. 2008; 27:1122–1131.
crossref
TOOLS
Similar articles